FDA's "Critical Path" Leads To Pharmaceutical Science Advisory Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee will discuss research opportunities under FDA's "Critical Path" initiative. Other topics for the Oct. 19-20 meeting include manufacturing, the risk-based GMP initiative, parametrics and generic drug equivalence.
You may also be interested in...
FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
FDA will also offer a revised bio-inequivalence proposal at an Oct. 20 Pharmaceutical Science Advisory Committee meeting. On Oct. 19, the committee will discuss FDA's Critical Path initiative, risk-based GMP progress and parametric interval testing.
FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
FDA will also offer a revised bio-inequivalence proposal at an Oct. 20 Pharmaceutical Science Advisory Committee meeting. On Oct. 19, the committee will discuss FDA's Critical Path initiative, risk-based GMP progress and parametric interval testing.
FDA Moving Toward PAT Standardized Nomenclature And Definitions
The process analytical technology component of FDA's drug quality initiative will be assisted by an independent standards-making effort and agency encouragement of comparability protocols. Part 11 and dispute resolution are other quality initiative components drawing industry input.